BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Posts Quarterly Earnings Results

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) released its quarterly earnings results on Tuesday. The company reported ($526.11) EPS for the quarter, FiscalAI reports.

BridgeBio Oncology Therapeutics Trading Up 6.6%

Shares of NASDAQ:BBOT traded up $0.53 during mid-day trading on Thursday, reaching $8.61. 254,819 shares of the company traded hands, compared to its average volume of 327,563. The stock’s 50 day simple moving average is $8.97. The company has a market capitalization of $689.75 million, a price-to-earnings ratio of -5.64 and a beta of 0.22. BridgeBio Oncology Therapeutics has a 52 week low of $7.60 and a 52 week high of $14.87.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BBOT shares. Weiss Ratings started coverage on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday, January 14th. They set a “sell (d+)” rating for the company. Stifel Nicolaus started coverage on shares of BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They set a “buy” rating and a $23.00 price target for the company. HC Wainwright upped their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Finally, Canaccord Genuity Group assumed coverage on shares of BridgeBio Oncology Therapeutics in a research report on Monday. They set a “buy” rating and a $23.00 price target for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. CIBC Private Wealth Group LLC bought a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at approximately $63,000. XTX Topco Ltd boosted its stake in BridgeBio Oncology Therapeutics by 22.4% in the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock worth $358,000 after purchasing an additional 5,249 shares during the period. Persistent Asset Partners Ltd bought a new position in BridgeBio Oncology Therapeutics in the 4th quarter worth approximately $107,000. Squarepoint Ops LLC bought a new position in BridgeBio Oncology Therapeutics in the 4th quarter worth approximately $144,000. Finally, Quadrature Capital Ltd bought a new position in BridgeBio Oncology Therapeutics in the 4th quarter worth approximately $162,000. 54.89% of the stock is currently owned by institutional investors.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.